Europe Hormonal Contraceptive Market

Gedeon Richter sold EUR 44.4 million of Drovelis, its estetrol and drospirenone pill, in the first half of 2026, up from EUR 31.8 million a year earlier, while its total contraception sales slipped to EUR 246.4 million from EUR 251.3 million, its H1 2026 earnings report shows. The Europe hormonal contraceptive market covers manufacturer sales of oral contraceptive pills, hormonal intrauterine systems, injectable contraceptives, subdermal implants, and patches and vaginal rings sold in Europe, both combined and progestin-only. Douglas Insights sizes it at USD 4.70 billion in 2025, about 49.5 million user-years of protection at a realised USD 95.01 each, and at USD 6.46 billion in 2035, a 3.22% compound annual growth rate (CAGR). The study is the Europe row of our worldwide Hormonal Contraceptive Market model and sits beside our U.S. Hormonal Contraceptive Market and Amenorrhea Market reports; every figure follows the Douglas Insights research methodology.

Which Europe hormonal contraceptive method earns the most: pills, intrauterine systems or implants?

Oral contraceptive pills earn the most, 52.0% of 2025 Europe hormonal contraceptive value or about USD 2.45 billion, Douglas Insights estimates. Subdermal implants grow fastest, at 5.6% a year to USD 650 million by 2035.

The pill leads because it is still the most used reversible method in Western Europe, though its share of value falls from 52.0% to about 48.0% by 2035 as women move to long-acting methods. Pill value grows only 2.4% a year: generic combined pills lose price every year, and the growth comes from newer branded pills. Gedeon Richter’s Drovelis sales rose 28.2% in Hungarian forint terms in the first half of 2026, its H1 2026 report shows, while Organon’s older Marvelon and Mercilon pills fell to USD 85 million in the first nine months of 2026 from USD 103 million, its 10-Q for the quarter to 30 September 2026 shows.

Hormonal intrauterine systems, USD 1.03 billion, hold 22.0% of value, a larger share than in any other region, and grow 4.4% a year to USD 1.59 billion. Patches and vaginal rings, USD 520 million, grow 2.4%; Organon’s non-US NuvaRing sales were USD 56 million in the first nine months of 2026 against USD 54 million a year earlier, its 10-Q shows. Implants, USD 380 million, grow fastest at 5.6%, and injectables, USD 330 million, grow 1.9%. Method values for 2035 sum to USD 6.39 billion, 0.98% below the headline.

How do Europe hormonal contraceptive hormone types and sales channels split?

Combined estrogen and progestin products carry about 63.0% of 2025 value, roughly USD 2.96 billion, Douglas Insights estimates, and progestin-only products 37.0%. Retail pharmacies sell about 62.0% of value.

Progestin-only products grow faster, at about 4.2% a year to USD 2.63 billion by 2035, against 2.6% for combined products, which reach USD 3.83 billion. Every intrauterine system, implant and most injectables are progestin-only, and progestin-only pills such as desogestrel and drospirenone-only tablets are gaining among women who cannot or prefer not to take estrogen, Douglas Insights estimates. Combined products hold their base through the pill, the patch and the ring.

Retail pharmacies, about USD 2.92 billion in 2025, grow 3.0% a year; hospitals and clinics, about USD 1.41 billion, grow 3.7% because intrauterine systems and implants are fitted there; and public programmes, about USD 376 million, grow 3.2%. In most European countries the buyer is a public insurer rather than the woman, so reimbursement lists decide which brands win.

What drives Europe hormonal contraceptive growth: long-acting methods, newer pills or wider reimbursement?

Four drivers add 4.52 gross points a year to Europe hormonal contraceptive revenue in our base case; three restraints remove 1.30, leaving the 3.22% rate. Realised price per user-year rises 2.91% a year, from USD 95.01 to about USD 126.57.

Shift to long-acting methods: 1.62 points

Long-acting methods are the largest driver, worth 1.62 points. Organon’s non-US Nexplanon sales rose to USD 248 million in the first nine months of 2026 from USD 225 million, about 10%, even as its US sales fell about 21% to USD 383 million, its 10-Q for the quarter to 30 September 2026 shows. Each Nexplanon rod holds 68 mg of etonogestrel, the summary of product characteristics states. Douglas Insights estimates that intrauterine systems and implants together rise from 30.0% of European value in 2025 to about 34.7% in 2035.

Newer branded pills: 1.20 points

Newer pills add 1.20 points. Drovelis sales reached EUR 44.4 million in the first half of 2026 against EUR 31.8 million a year earlier, and Richter’s management said the brand “contributed materially to sales growth”, its H1 2026 report states. Douglas Insights estimates that a branded estetrol or drospirenone-only pill realises about USD 130 to USD 200 per user-year against USD 25 to USD 45 for a generic combined pill, so each 1% of users who switch adds about USD 60 million of value.

Wider reimbursement: 0.95 points

Wider public payment adds 0.95 points. Luxembourg reimburses contraceptives at 100% with no age limit from 1 April 2023, the Luxembourg government announced, and Vorarlberg in Austria is piloting free contraception with counselling, the European Parliamentary Forum (EPF) said on 24 February 2026. Douglas Insights estimates that free or fully reimbursed schemes cover about 38% of women aged 15 to 49 in the region in 2025, rising to about 50% by 2032.

Pharmacy access: 0.75 points

Easier pharmacy access adds the last 0.75 points. Poland lets pharmacists dispense emergency contraception without a doctor’s visit, and pharmacist-led supply of the pill is spreading, the EPF Contraception Policy Atlas 2026 notes. Summed, 1.62 + 1.20 + 0.95 + 0.75 = 4.52 points, a Douglas Insights estimate; after restraints, the 2.91% price leg multiplied by the 0.30% volume leg gives the 3.22% revenue rate.

What holds back the Europe hormonal contraceptive market: generic erosion, fewer women or hormone-free methods?

Three restraints remove 1.30 points a year: generic price erosion takes 0.60 points, a shrinking population of women aged 15 to 49 takes 0.40 points and the shift to hormone-free methods 0.30 points.

Generic erosion is the largest drag. Organon’s Marvelon and Mercilon sales fell about 17% in nine months, and Richter’s contraception sales fell 10.1% in forint terms in the first half of 2026 even though Drovelis grew, the company filings above show, because older combined pills face tender and generic price cuts across the region. Douglas Insights estimates that the realised price of a generic combined pill falls about 3% a year to 2035.

Demography takes 0.40 points: the number of women aged 15 to 49 in Europe declines by about 0.3% a year over the decade, a Douglas Insights estimate, which holds user-years to 0.30% growth even as use rises. Hormone-free methods take the final 0.30 points as some younger women move to copper coils, fertility-awareness apps and condoms. Bayer, the largest supplier of intrauterine systems, does not split contraception in its third-quarter results of 3 November 2026, in which pharmaceutical division sales rose 8.0% to EUR 4.68 billion.

Which European country buys the most hormonal contraceptives, and where does value grow fastest?

Germany buys the most Europe hormonal contraceptive value, about USD 890 million or 19.0% of 2025 sales. Central and Eastern Europe grows fastest, at 4.1% a year to USD 980 million by 2035, from the region’s lowest use rates.

Germany leads on population and high pill use, but grows only 2.6% a year because its pill use has fallen for a decade, a Douglas Insights estimate. France, USD 750 million, grows 3.0% and was ranked among the top five countries for contraceptive access, with the United Kingdom, Portugal, Luxembourg and Belgium, in the EPF atlas of 24 February 2026, which mapped 47 countries. The United Kingdom, USD 710 million, grows 3.6% on pharmacy supply and long-acting methods; Italy, USD 380 million, grows 3.3%; and Spain, USD 330 million, 3.5%.

The Nordic countries, USD 380 million, grow 3.0% from the region’s highest intrauterine system use. Central and Eastern Europe, including Poland, Hungary and Slovakia, which the EPF ranked among the five lowest for access with Russia and Türkiye, grows fastest at 4.1% from a low base. The rest of Europe, USD 610 million, grows 3.2%. Country values sum to USD 4.86 billion in 2026, 0.03% above the headline, and USD 6.48 billion in 2035, 0.41% above it.

Which companies lead the Europe hormonal contraceptive market, and how concentrated is it?

Bayer leads the Europe hormonal contraceptive market with about 18.0% of 2025 value, a Douglas Insights estimate built on its intrauterine systems and drospirenone pills, ahead of Gedeon Richter at 8.0%. The top six hold about 46.0%.

The market is far less concentrated than mobile or device markets because most pill value is generic. Gedeon Richter’s Women’s Healthcare sales in Europe reached EUR 332.0 million in the first half of 2026 against EUR 304.4 million a year earlier, flat in forint terms, its H1 2026 report shows; that figure includes menopause and fibroid products, so only part of it is contraception.

No company splits contraceptive sales by European country, so every share in the table is a Douglas Insights estimate. Pfizer, Perrigo through HRA Pharma, Sandoz, Zentiva and many national generic makers share most of the remaining 54.0%.

What does a year of hormonal contraception cost in Europe, and how fast does the price rise?

A year of hormonal protection realises an average USD 95.01 for manufacturers in Europe in 2025, Douglas Insights estimates, 31.3% above the USD 72.35 world average, rising 2.91% a year to about USD 126.57 in 2035.

The European average sits above the world figure because intrauterine systems, branded pills and rings make up more of the mix than in Asia, Latin America or Africa, where donor-priced injectables dominate. Douglas Insights puts the realised price at about USD 25 to USD 45 per user-year for a generic combined pill, USD 130 to USD 200 for a branded newer pill and USD 110 to USD 160 for a ring or patch, with intrauterine systems and implants spread over several years of use.

The price leg is a mix effect, not a list-price effect. Generic prices fall about 3% a year, but each user who moves from a generic pill to a long-acting method or a branded pill raises the average. Price per user-year reaches about USD 97.77 in 2026, and the 2.91% leg is the part of growth that does not depend on more women using contraception.

How fast are long-acting methods replacing the pill in Europe?

Intrauterine systems and implants take about 30.0% of European value in 2025 and about 34.7% by 2035, Douglas Insights estimates, while the pill falls from 52.0% to about 48.0%.

Two forces drive the switch. Long-acting methods cost the health system less over five to eight years of use than repeat pill prescriptions, so insurers and national health services promote them; and they remove the daily-dosing failures that make typical-use pill effectiveness lower than perfect use. The fastest gains are in the United Kingdom, France and the Nordic countries, where clinics fit devices at scale.

The switch is limited by fitting capacity. Douglas Insights estimates that a fitted device needs about 20 minutes of trained clinician time, and that waiting lists for fittings slow uptake in Germany, Italy and much of Central and Eastern Europe. Organon’s 10% non-US Nexplanon growth in 2026 shows the demand is there where clinics can meet it.

The value effect of the switch is uneven across the decade. Because a single intrauterine system or implant covers three to eight years, a wave of fittings lifts sales in the year of insertion and then pauses until replacement, Douglas Insights estimates, so the method shares in our tables move in steps rather than in a straight line. We model the first replacement wave for devices fitted in 2026 and 2027 arriving from 2031, which adds about 0.2 points to the long-acting growth rate in 2031 to 2033. Implant growth of 5.6% a year takes the method from USD 380 million to USD 650 million, while intrauterine systems add about USD 560 million of value over the same ten years.

Which rules govern Europe hormonal contraceptives, from prescription status to reimbursement?

Three layers govern Europe hormonal contraceptives: prescription status set nationally, reimbursement rules set by each health system, and safety and product information set through the European Medicines Agency and national regulators.

The reimbursement layer moves the market most. Luxembourg pays 100% with no age limit from 1 April 2023, the government announcement states, and the EPF atlas of 24 February 2026 found that only 9 countries, about one sixth of the continent, provide excellent public websites on contraception. Douglas Insights estimates that each country that moves to full reimbursement for women under 25 adds about 4% to that country’s user-years within three years.

The prescription layer is loosening slowly. Most European countries still require a prescription for the pill, but pharmacist supply is spreading for progestin-only pills and emergency contraception, the EPF atlas notes. The safety layer sets product information for every method; each Nexplanon rod, for example, must carry its 68 mg dose and release profile in the summary of product characteristics.

What if reimbursement widens faster or generics bite harder: how large is the Europe hormonal contraceptive market in 2035?

The Europe hormonal contraceptive market ends 2035 between USD 5.67 billion and USD 7.18 billion across three cases, around a USD 6.46 billion base. Reimbursement and the pace of the long-acting switch set most of the spread.

In the slower case reimbursement stalls, the hormone-free shift speeds up and generic prices fall faster, taking 0.60 points off volume and 0.71 points off price. In the faster case three or more large countries extend free contraception to women under 30 and clinics expand fitting capacity, adding 0.50 points to volume and 0.59 points to price. One extra point of yearly revenue growth adds about USD 650 million to 2035 value, a Douglas Insights estimate.

Company signals bracket the base case. Richter’s newer pill grew 28.2% while its older contraception fell 10.1% in forint terms, and Organon’s non-US implants grew 10% while its older pills fell about 17%, the filings above show. Our 3.22% rate sits between the branded gains and the generic losses.

Douglas Exclusive: the Europe Contraceptive Switch Ledger

The Contraceptive Switch Ledger is a Douglas Insights model built from 10 inputs: 6 company figures, 3 policy documents and 1 product label. It tracks how users moving between methods change value per user-year.

The finding, a Douglas Insights estimate: about 1.1 million European users a year move from a generic pill to a long-acting method or a branded newer pill, and each switch raises realised value per user-year by about USD 85 to USD 130. That mix shift alone adds about USD 120 million a year, more than the whole effect of volume growth.

The ledger changes how to read the region. A European supplier’s growth depends less on how many women use hormonal contraception than on which method they use, so companies with long-acting devices and branded newer pills gain share even in a flat-volume market, while generic pill makers lose about 3% of price a year.

How does the methodology turn 49.5 million user-years into USD 4.70 billion?

Our methodology multiplies about 49.5 million European user-years of hormonal protection by a realised USD 95.01 each to reach USD 4.70 billion in 2025, then grows volume 0.30% and price 2.91% a year.

The model covers 5 methods, 2 hormone types, 3 channels and 8 countries or sub-regions, using 58 data points, 16 sourced and 42 modelled. User-years come from method-use surveys, prescription data and company volumes; prices come from realised manufacturer prices by method, all Douglas Insights estimates. Arithmetic: 49.5 million x USD 95.01 = USD 4.70 billion; USD 4.70 billion x (1.0030 x 1.0291)^10 = USD 6.46 billion. User-years reach about 49.65 million in 2026 and 51.0 million in 2035.

Two cross-checks agree. First, USD 4.70 billion is the Europe row of our worldwide model, 24.2% of its USD 19.43 billion total, and our 3.22% rate equals that row’s rate. Second, 49.5 million user-years are 18.4% of the 268.6 million in the worldwide model. AI tools help draft the text and automated checks test the arithmetic and links; the Douglas Insights research desk chooses the sources, builds the model and approves publication, as our editorial standards explain.

Sources

1. Gedeon Richter (Budapest Stock Exchange) Earnings report H1 2026 (2026)
2. Organon, filed with the SEC Form 10-Q for the quarter ended 30 September 2026 (2026)
3. Bayer Bayer Q3 2026 results (2026)
4. European Parliamentary Forum for Sexual and Reproductive Rights How accessible is contraception in Europe in 2026? (2026)
5. Government of Luxembourg Contraceptives reimbursed at 100% with no age limit from 1 April (2023)
6. electronic medicines compendium Nexplanon 68 mg implant summary of product characteristics (2025)

What counts in the Europe hormonal contraceptive study, and what is excluded?

The Europe hormonal contraceptive study counts manufacturer sales of hormonal contraceptives sold in Europe, at realised prices after rebates. Emergency contraception, copper coils, condoms, menopause hormone therapy and fibroid treatments such as Ryeqo are excluded.

The study splits value by 5 methods, 2 hormone types, 3 channels and 8 countries or sub-regions: Germany, France, the United Kingdom, Italy, Spain, the Nordic countries, Central and Eastern Europe, and the rest of Europe. Worldwide figures appear in our Hormonal Contraceptive Market report.